Logo Logo Logo Logo Logo
  • Home
  • Expertise
  • Consulting Services
  • Our Platforms
  • News
  • Careers
  • Contact
  • Home
  • Expertise
  • Consulting Services
  • Our Platforms
  • News
  • Careers
  • Contact
  • October 20, 2017

    ISPOR 20th Annual European Congress

    News
  • October 20, 2017

    ISPOR 20th Annual European Congress

    News
  • October 23, 2017

    Singapore’s HTA decisions in Prismaccess and Evalumade

    News
  • October 23, 2017

    Singapore’s HTA decisions in Prismaccess and Evalumade

    News
  • November 30, 2017

    Peru’s HTA Agency reports in Prismaccess & Evalumade platforms

    News
  • November 30, 2017

    Peru’s HTA Agency reports in Prismaccess & Evalumade platforms

    News
  • January 09, 2018

    PRIORITIS heads a market access training at Paris-Dauphine University

    News
  • January 09, 2018

    PRIORITIS heads a market access training at Paris-Dauphine University

    News
  • January 31, 2018

    RWD and RWE will play an increasing role in health care decisions

    News
  • January 31, 2018

    RWD and RWE will play an increasing role in health care decisions

    News
  • February 09, 2018

    Annual report from French Economic Committee (CEPS)

    News
  • February 14, 2018

    2018, innovations and new economic models

    News
  • February 19, 2018

    Prismaccess’ data in an international study in oncology

    News
  • February 19, 2018

    Données Prismaccess dans une étude de l’INCa

    News
  • February 26, 2018

    Spain, a new financing model for high economic-impact medicines

    News
  • February 26, 2018

    Spain, a new financing model for high economic-impact medicines

    News
  • March 13, 2018

    Prioritis at Pharma Pricing and Market Access congress London

    News
  • May 14, 2018

    Prioritis at ISPOR Baltimore

    News
  • May 30, 2018

    FDA wishes faster approval for gene therapies

    News
  • June 11, 2018

    Prioritis at ISPOR Baltimore

    News
  • July 05, 2018

    Drug Reimbursement and Pricing Policy in Taiwan

    News
  • October 09, 2018

    Evaluation du médicament au Japon dans Prismaccess

    News
  • October 09, 2018

    Japanese decisions in Prismaccess and Evalumade

    News
  • November 05, 2018

    Prioritis at ISPOR Barcelona – Stand 201

    News
  • February 18, 2019

    Prioritis at Pricing & Market Access Amsterdam

    News
  • October 22, 2019

    Prioritis at ISPOR Copenhagen stand C2-037

    News
  • February 12, 2020

    EMA after Brexit? Prioritis continues to monitor the changes

    News
  • January 08, 2021

    Best wishes from Prioritis

    News
  • January 14, 2021

    New routes to marketing approval in Great Britain

    News
  • January 20, 2021

    Innovative CAR-T cell therapy set to be reimbursed by NICE

    News
  • February 10, 2021

    Cost-effectiveness and budget impact to be included in new IPTs

    News
  • February 25, 2021

    Japan’s First Pricing Reform Since 2013, expected in April 2021

    News
  • March 19, 2021

    UK Cancer Drugs Fund to be expanded for non-cancer therapies

    News
  • October 06, 2021

    New indications in oncology not easily accessible to French patients

    News
  • October 06, 2021

    Les nouvelles indications en oncologie peu accessibles au patient français

    News
  • July 11, 2022

    China available as an optional add-on for Prismaccess

    News
An IQVIA Business

logo
Contact us

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry dedicated to delivering actionable insights. Learn more at www.iqvia.com

Prioritis United Kingdom
United Kingdom
Prioritis Ltd
221 Pentonville Road King’s Cross
London N1 9JY – United Kingdom
tel. +44 7908 126 651
contact@prioritis.com
Prioritis France
France
Prioritis SAS
12 av Victor Hugo
75116 Paris
tel. +33 1 45 00 25 25 contact@prioritis.com